Clinical trials: Major Depressive Disorder, Recurrent
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder, Chronic Major Depression, Recurrent
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective…
- Trial name
- Re-EMBARC (NCT05892744)
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas at Austin
Major Depressive Disorders
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive…
- Trial name
- NCT00825019
- Testing
- amibegron (SR58611A), paroxetine
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- Sanofi
Major Depressive Disorder, Recurrent, Mild, Depressive Disorder, Major
Cortical Excitability and Inhibition in MDD
The purpose of this study is to learn if measures of brain activity are different in children and adolescents with depression who are in different stages of treatment.
- Trial name
- NCT01718730
- Testing
- Transcranial Magnetic Stimulation (TMS), Magnetic Resonance Spectroscopy and Imaging
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Bipolar 1 Disorder
Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning
This study was designed to evaluate the efficacy of the mobile application named Circadian Rhythm for Mood (CRM), which was developed to prevent recurring episodes of mood disorders (major depressive disorders, bipolar disorders…
- Conditions
- Major Depressive Disorder, Bipolar 1 Disorder, Bipolar II Disorder
- Trial name
- NCT05400785
- Testing
- Circadian Rhythms for Mood (CRM) application - Active
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Hucircadian
Major Depressive Disorder (MDD)
Predictors of Relapse in Major Depressive Disorder (PERFORM-D)
Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are…
- Trial name
- PERFORM-D (NCT06746155)
- Where
- 9 sites in Canada
- Volunteers
- 252 people
- Sponsor
- Abraham Nunes
Seasonal Affective Disorder, Mood Disorders
Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)
We are offering non-pharmacologic therapy for alleviation of symptoms associated with depressed mood that recurs annually in fall or winter.
- Conditions
- Seasonal Affective Disorder, Mood Disorders, Depression
- Trial name
- NCT00006517
- Testing
- bright light box, dawn simulator, high-output negative ion generator
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- New York State Psychiatric Institute
Seasonal Affective Disorder (SAD), Winter Depression
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Major depression is a highly prevalent, chronic, and debilitating mental health problem with significant social cost that poses a tremendous economic burden.
- Conditions
- Seasonal Affective Disorder (SAD), Winter Depression, Major Depressive Disorder, Recurrent, With Seasonal Pattern
- Trial name
- NCT01714050
- Testing
- Cognitive-Behavioral Therapy (CBT), Light Therapy (LT)
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Vermont
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an…
- Trial name
- NCT00878748
- Testing
- Effexor XR, Effexor XR discontinue
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression
The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or…
- Trial name
- NCT00928980
- Testing
- Mindfulness Based Cognitive Therapy, Optimal Medical Care
- Where
- 13 sites in Netherlands
- Volunteers
- 317 people
- Sponsor
- Radboud University Medical Center
Major Depression
Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression
Major Depressive Disorder affects approximately 16% of the adult population over the lifetime. Controlled studies indicate that short-term antidepressive medications or psychotherapy produce full remission in only about 46% of…
- Trial name
- NCT00220623
- Testing
- antidepressant medications, flexible drug choice, CBT, Psychodynamic or Supportive Psychotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Major Depressive Episode
MRS and Medication Response: A Pilot Study
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild
- Trial name
- NCT03254342
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Tobacco Use Disorder, Mental Illness
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
The study team will conduct a Multisite Randomized Controlled Trial to evaluate the advantages and disadvantages of two approaches for quitting smoking among people with serious mental illness (SMI).
- Conditions
- Tobacco Use Disorder, Mental Illness, Recurring Major Depressive Disorder, Bipolar Disorder
- Trial name
- MTQT (NCT05030272)
- Testing
- Quit on the Go App (formerly "Learn to Quit " App), Brief advice, Nicotine patch
- Where
- 3 sites in United States
- Volunteers
- 343 people
- Sponsor
- Wake Forest University Health Sciences
Major Depressive Disorder
The Effect of Fish Oil in Major Depressive Disorder
The whole study was divided into two major parts: (A) the 12-week, double-blind, randomized controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to moderate major depressive disorder.
- Trial name
- NCT00816322
- Testing
- Omega-3 fatty acids
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Science and Technology Council, Taiwan
Late-life Depression, Major Depressive Disorder
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
This study addresses the unmet medical problem of insufficient treatment of late life depression (LLD). Compared with depression in early adulthood, treatment options of LLD are limited.
- Conditions
- Late-life Depression, Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent
- Trial name
- CBTlate (NCT03735576)
- Testing
- Psychotherapy, Questionnaires, Magnetic Resonance Imaging
- Where
- 7 sites in Germany
- Volunteers
- 250 people
- Sponsor
- University of Cologne
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder, Recurrent
Investigation of Brain Network Dynamics in Depression
This research study is being done to gain a better understanding about brain networks that may be involved in depression. The investigators plan to examine how these networks change after the brain is stimulated with…
- Trial name
- NCT01931995
- Testing
- TMS positively correlated DLPFC, TMS to negatively correlated DLPFC
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Wellness Monitoring for Major Depressive Disorder
The Wellness Monitoring for Major Depressive Disorder (MDD) study is a prospective, longitudinal, observational study aimed at identifying biomarkers of relapse in MDD.
- Trial name
- CBN-Well (NCT02934334)
- Testing
- Observational
- Where
- 5 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sidney Kennedy